U.S. market Open. Closes in 2 hours 12 minutes

AKYA | Akoya Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.1750 - 2.2900
52 Week Range 1.8800 - 6.31
Beta 1.47
Implied Volatility 321.06%
IV Rank 44.80%
Day's Volume 37,311
Average Volume 152,830
Shares Outstanding 49,563,400
Market Cap 109,535,114
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 2021-04-16
Valuation
Profitability
Growth
Health
P/E Ratio -1.91
Forward P/E Ratio N/A
EPS -1.16
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 330
Country USA
Website AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
*Chart delayed
Analyzing fundamentals for AKYA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see AKYA Fundamentals page.

Watching at AKYA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AKYA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙